Performance analysis of Rein Therapeutics (RNTX)
Annual Return
Over the past 3 years, RNTX has had an average annual return of -22.21%, underperforming the benchmark SPY, which returned +19.31% annual.
Over the past 5 years, RNTX has had an average annual return of -47.74%, underperforming the benchmark SPY, which returned +12.55% annual.
Over the past 10 years, RNTX has had an average annual return of -9.30%, underperforming the benchmark SPY, which returned +14.95% annual.
Since Nov 1, 1999, RNTX has had an average annual return of -13.12%, underperforming the benchmark SPY, which returned +8.46% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.19% | -49.53% | -24.61% | +28.59% | -78.94% | -45.87% | +81.46% | -31.77% | -92.03% | +9,307.12% | +0% | +0% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
| +0% | -77.54% | -75.06% | -24.53% | +263.07% | +21.67% | -31.05% | -58.01% | +2.68% | -14.85% | -11.90% | +70.25% |
| 2002 | 2001 | 2000 | 1999 | ||||||||
| +1.94% | -32.99% | +12.12% | +13.79% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +12.19% | -12.53% | +14.33% | +4.18% | -18.18% | -6.21% | -18.82% | -27.19% | |||||
| 2025 | -14.35% | +6.08% | -15.28% | -3.28% | +13.98% | -28.25% | -16.84% | +19.31% | -17.49% | +36.71% | +0.23% | -26.10% | -49.53% |
| 2024 | +44.95% | +11.73% | +34.21% | -31.35% | -29.64% | -13.48% | -20.55% | +14.50% | +40.43% | +16.39% | -30.55% | -19.65% | -24.61% |
| 2023 | +17.28% | -46.41% | -16.79% | +17.25% | +2% | +20.78% | -3.44% | -3.98% | -8.52% | -22.91% | +81.11% | +43.76% | +28.59% |
| 2022 | -17.23% | -8.44% | +20.10% | -13.73% | -4.47% | -38.43% | -26.85% | -2.67% | +11.66% | -3.25% | -30.73% | -14.40% | -78.94% |
| 2021 | +75.98% | -16.94% | -5.93% | -16.77% | +3.35% | +1.64% | -17.61% | +11.65% | -11.30% | -14.70% | -29.09% | -8.76% | -45.87% |
| 2020 | +18.32% | -13.72% | -43.26% | +64.50% | +196.65% | -27.15% | -25.43% | +45.45% | +0.78% | -10.85% | -5.22% | -4.59% | +81.46% |
| 2019 | +30.95% | +50.91% | +17.47% | -11.80% | -41.86% | -28.01% | -30.55% | +45.98% | -8.20% | -34.33% | +9.11% | +19.37% | -31.77% |
| 2018 | -12.43% | -11.05% | -0.97% | -37.52% | +1.57% | +5.04% | -42.99% | -5.50% | -5.82% | -14.54% | -7.66% | -61.29% | -92.03% |
| 2017 | +0% | +0% | +0% | +0% | +0% | +9,851.46% | +14.80% | -8.91% | +14.75% | -10.01% | -6.81% | -6.06% | +9,307.12% |
Drawdown analysis of Rein Therapeutics (RNTX)
The maximum drawdown for the RNTX was -99.72%, occurring on Jul 20, 2026. This drawdown has not yet recovered.
The current RNTX drawdown is -99.72%.
Since Nov 1, 1999 RNTX has experienced the following drawdowns:
- 50% or more: 3 times
- 40% or more: 3 times
- 30% or more: 3 times
- 20% or more: 4 times
- 10% or more: 10 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.72% | Oct 4, 2017 | 2207 | Jul 20, 2026 | Ongoing | Ongoing | Ongoing |
| -97.95% | Feb 17, 2004 | 2473 | Dec 12, 2013 | 892 | Jun 29, 2017 | 3365 |
| -64.00% | Mar 20, 2000 | 396 | Oct 18, 2001 | 579 | Feb 9, 2004 | 975 |
| -26.18% | Jan 4, 2000 | 10 | Jan 19, 2000 | 38 | Mar 14, 2000 | 48 |
| -18.78% | Sep 7, 2017 | 6 | Sep 15, 2017 | 11 | Oct 2, 2017 | 17 |
| -17.25% | Jul 7, 2017 | 35 | Aug 25, 2017 | 8 | Sep 7, 2017 | 43 |
| -16.15% | Nov 2, 1999 | 3 | Nov 5, 1999 | 5 | Nov 12, 1999 | 8 |
| -13.14% | Dec 21, 1999 | 7 | Dec 31, 1999 | 2 | Jan 4, 2000 | 9 |
| -11.43% | Nov 22, 1999 | 4 | Nov 29, 1999 | 4 | Dec 3, 1999 | 8 |
| -10.81% | Dec 9, 1999 | 3 | Dec 14, 1999 | 5 | Dec 21, 1999 | 8 |
| -3.84% | Mar 14, 2000 | 1 | Mar 15, 2000 | 2 | Mar 17, 2000 | 3 |
| -3.06% | Nov 15, 1999 | 1 | Nov 16, 1999 | 4 | Nov 22, 1999 | 5 |
| -2.53% | Feb 10, 2004 | 3 | Feb 13, 2004 | 1 | Feb 17, 2004 | 4 |
| -2.30% | Jul 3, 2017 | 1 | Jul 5, 2017 | 1 | Jul 6, 2017 | 2 |
| -0.07% | Oct 2, 2017 | 1 | Oct 3, 2017 | 1 | Oct 4, 2017 | 2 |